Keyword: Kymriah (tisagenlecleucel)
Less than a year after buying a U.S. plant from AstraZeneca, Novartis’ biotech AveXis has it ready for production of its gene therapy Zolgensma.
Hamstrung by manufacturing issues, Novartis' CAR-T med Kymriah has lagged behind expectations. A new European facility could help its cause.
Novartis' effort to cut up to $2 billion out of production units will play out next at its site in Cork, Ireland.
New CMS rules have removed some restrictions on healthcare providers that could in turn boost uptake of Gilead's and Novartis' CAR-T drugs.
Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”
Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.
Takeda releases first post-Shire guidance; Indian generics makers are named in a price-fixing suit; Daiichi's quizartinib fails at FDA.
The price, though a discount from its U.S. sticker, makes Kymriah the most expensive treatment offered on the Japanese public insurance system.
With FDA approval of Zolgensma expected soon, Novartis CEO Vasant Narasimhan is confident that the company's manufacturing network will meet demand.
With Yescarta on the market and other CAR-Ts on their way, Gilead’s Kite Pharma planted the flag for another manufacturing site.